September 2019
Endpoints essay on weak correlation of surrogate markers with OS.
https://endpts.com/cancer-trials-aimed-at-surrogate-targets-miss-bigger-mark-study/
New BMJ study by Naci et al. of EMA approvals 2014-2016.
Surrogate Markers have poor correlates to outcomes
https://www.bmj.com/content/366/bmj.l5221
With Op Ed by Mintzes
https://www.bmj.com/content/366/bmj.l5399
With Essay by Naci themselves
https://blogs.bmj.com/bmj/2019/09/18/gauging-the-validity-of-cancer-drug-trials-a-call-for-collaboration/
With Trackback to 2018 article in JAMA Internal Medicine by Kovic et al.
(PFS not correlated to QOL)
https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2705082
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.